Reflecting on XVI Years: How FDA & USDA Regulatory Law Has Evolved (And What Comes Next)

Celebrating

Sixteen Years of FDA Law

2010 — 2026

Our firm celebrates 16 years of practice exclusively dedicated to the complexities of FDA and USDA regulatory law.

When I first opened our doors, the regulatory landscape for food, drugs, medical devices, and cosmetics looked vastly different. We were operating before the Food Safety Modernization Act (FSMA) completely overhauled the food supply chain, before the FDA began heavily regulating digital health and Software as a Medical Device (SaMD), and long before MoCRA fundamentally rewrote the rules for the cosmetic industry.

Over the past decade and a half, we have guided domestic and international companies through these sweeping paradigm shifts. Achieving this 16-year milestone has prompted me to reflect on what has changed in the life sciences and consumer goods sectors—and, more importantly, what remains exactly the same.

The Shift Toward “Continuous Readiness”

If there is one defining theme of the last 16 years, it is the shift away from point-in-time compliance toward continuous, verifiable readiness. The agencies have modernized, and their oversight has become highly data-driven.

We see this actively playing out right now. The FDA’s recent rollout of the Quality Management System Regulation (QMSR) demands that medical device manufacturers fully integrate global ISO standards into their daily operations. Similarly, the FDA’s new pilot program utilizing artificial intelligence to select facilities for one-day “safety screening” inspections means that an algorithm—not just a routine cycle—might trigger a knock at your door.

In my practice, whether I am counseling developers through complex 510(k) premarket pathways or drafting Corrective and Preventive Action (CAPA) responses to a Form FDA 483, the underlying lesson is the same: the FDA’s tolerance for disorganized records or retroactive compliance is effectively zero.

Building Defensible Global Supply Chains

Another major evolution over the past 16 years has been the intense globalization of the supply chain, paired with increased federal scrutiny at the border.

Today, a single product might involve an overseas contract manufacturer, a domestic distributor, and a complex web of raw material suppliers. We have spent the last 16 years helping international entities navigate U.S. market entry and serving as authoritative U.S. Agents. What we have learned is that robust Quality Agreements and rigorous supplier qualifications are no longer just good business practices—they are your primary legal defense against import alerts, Warning Letters, and mandatory recalls.

Looking Ahead to the Next Era

As we look toward the future, the integration of artificial intelligence in regulatory screening, the shifting administrative dynamics in Washington, D.C., and the rapid advancement of medical product technology will present unprecedented challenges to regulated industries.

Whether we are advising an emerging digital health platform on engineering boundaries for an AI wellness application or helping a legacy cosmetics brand structure its safety substantiation data for MoCRA renewals, our firm’s approach remains unchanged. We combine deep substantive knowledge with a practical understanding of how federal agencies operate to deliver defensible, commercial-ready solutions.

To our clients, co-counsel, and industry partners: thank you for trusting us to protect your innovations, your supply chains, and your operations over the last 16 years. We look forward to continuing to serve as your dedicated regulatory counsel in the chapters to come.